[The efficacy of topiramate (topamax) in the treatment of resistant epilepsy in children].
Authors presented the data on the efficacy and tolerability of the new anticonvulsant drug topiramate (topamax) in the treatment of 110 children aged from 6 months to 16 years with pharmacoresistant types of epilepsy including 42 patients with tuberous sclerosis. The medication dosage varied from 1 to 20 mg/kg daily. As a monotherapy the drug was used in 28 children, in the other cases it was combined with different anticonvulsant medications. Topiramate was effective in 78% patients; complete remission has been achieved in 35% cases. Side-effects were observed in 17% patients but they were transient and did not result in the drug withdrawal. The results of the study allowed to recommend the drug as an add-on and monotherapy in the treatment of resistant epilepsy.
Dorofeeva
M Iu
MIu
Ermakov
A Iu
AIu
Belousova
E D
ED
D000293:Adolescent; D000927:Anticonvulsants / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D002220:Carbamazepine / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D004827:Epilepsy / Q000188:drug therapy*; D005260:Female; D005632:Fructose / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D000077213:Lamotrigine; D008297:Male; D000077236:Topiramate; D016896:Treatment Outcome; D014227:Triazines / Q000627:therapeutic use; D014635:Valproic Acid / Q000627:therapeutic use; D020888:Vigabatrin / Q000627:therapeutic use
D000927:Anticonvulsants; D014227:Triazines; D000077236:Topiramate; D005632:Fructose; D002220:Carbamazepine; D014635:Valproic Acid; D020888:Vigabatrin; D000077213:Lamotrigine